These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15344566)

  • 1. [Management of neuropathic bladder in multiple sclerosis].
    Pappalardo A; Patti F; Reggio A
    Clin Ter; 2004 May; 155(5):183-6. PubMed ID: 15344566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder management in multiple sclerosis.
    Yang CC
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):673-86. PubMed ID: 24314685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Help for patients with multiple sclerosis: current diagnostic and treatment possibilities in neurogenic disorders of bladder emptying].
    Zwergel U; Wullich B; Jost WH; Zwergel T
    Dtsch Med Wochenschr; 1998 May; 123(22):707-12. PubMed ID: 9645188
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacotherapy of the overactive bladder and advances in drug delivery.
    Cannon TW; Chancellor MB
    Clin Obstet Gynecol; 2002 Mar; 45(1):205-17. PubMed ID: 11862073
    [No Abstract]   [Full Text] [Related]  

  • 6. The overactive bladder in multiple sclerosis.
    Fingerman JS; Finkelstein LH
    J Am Osteopath Assoc; 2000 Mar; 100(3 Suppl):S9-12. PubMed ID: 10763312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
    Brubaker L; Chapple C; Coyne KS; Kopp Z
    Urology; 2006 Aug; 68(2 Suppl):3-8. PubMed ID: 16908335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conservative management in neurogenic bladder dysfunction.
    Aslan AR; Kogan BA
    Curr Opin Urol; 2002 Nov; 12(6):473-7. PubMed ID: 12409875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis and the neurogenic bladder.
    Rashid TM; Hollander JB
    Phys Med Rehabil Clin N Am; 1998 Aug; 9(3):615-29. PubMed ID: 9894113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [More quality of life again with tolterodine].
    Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study.
    McClurg D; Ashe RG; Marshall K; Lowe-Strong AS
    Neurourol Urodyn; 2006; 25(4):337-48. PubMed ID: 16637070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication update.
    Slagle M
    South Med J; 2002 Feb; 95(2):188-91. PubMed ID: 11846243
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactive bladder. Strategies for better recognition and management.
    Smith DA
    Adv Nurse Pract; 2004 Mar; 12(3):26-33; quiz 34. PubMed ID: 15038182
    [No Abstract]   [Full Text] [Related]  

  • 20. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.